Celltrion’s Inflectra, a Biosimilar to Treat Ulcerative Colitis and Crohn’s Disease, Gets FDA Approval

Celltrion’s Inflectra, a Biosimilar to Treat Ulcerative Colitis and Crohn’s Disease, Gets FDA Approval
 Celltrion recently announced it has received approval from the U.S. Food and Drug Administration (FDA) for the use of its Inflectra (biosimilar infliximab) product for all indications of the reference product, Janssen Biotech Inc.’s Remicade (infliximab), originally licensed in 1998. Inflectra is sold in Europe as Remsima. Inflectra is the first biosimilar monoclonal antibody (mAb) medication and

Knowledge is power when living with IBD.

Get access to the web’s leading IBD news & insights for as little as 16¢/day.
Subscribe or to access all post and page content.

One comment

  1. Barry Saunders says:

    I have crohns and am having trouble controling it had surgery but coming back need cheaper medication

Leave a Comment

Your email address will not be published. Required fields are marked *